All articles tagged with #7 oh
Florida has become the first state to ban the sale of 7-hydroxymitragynine (7-OH), a potent kratom byproduct that acts like an opioid, classifying it as a Schedule I controlled substance following FDA recommendations, aiming to curb its use and potential health risks.
The FDA is targeting 7-hydroxymitragynine (7-OH), a potent, morphine-like compound found in kratom, which has gained popularity for its pain-relieving and mood-enhancing effects. While some advocate for its benefits, concerns about its high potency, potential for addiction, and unregulated production have led to calls for stricter regulation to ensure safety. Kratom's legal status varies across states, and the compound's effects are not fully understood, raising public health concerns.
The FDA has recommended classifying the synthetic compound 7-hydroxymitragynine (7-OH), found in unregulated products sold at gas stations and online, as a Schedule I illicit substance due to its potent opioid-like effects and associated health risks, prompting a review by the DEA.
The FDA is recommending scheduling 7-hydroxymitragynine (7-OH), a potent opioid byproduct of kratom, under the Controlled Substances Act to prevent abuse and protect public health, especially among youth, amid concerns over its increasing availability and potential for addiction.
The FDA is recommending regulatory action to control 7-hydroxymitragynine (7-OH), a potent opioid byproduct of the kratom plant, due to its abuse potential and presence in unregulated products, especially those appealing to youth. The agency emphasizes the risks and is working to prevent a new wave of opioid addiction by alerting healthcare professionals and consumers, and collaborating with the DEA for scheduling.
The FDA and health officials are planning to announce measures to crack down on synthetic products containing 7-OH, a potent opioid-like substance derived from kratom, which is increasingly found in various consumer products and raises safety concerns.